Shareholders Approve Eli Lilly Acquisition Scheme
CNTA has more than doubled off its 52-week low of $11.77.
Summary
Centessa Pharmaceuticals plc shareholders have approved the acquisition by Eli Lilly and Company, clearing a significant hurdle for the deal's completion.
Key Events · M&A and Partnerships · CNTA
-
Shareholder Approval Secured
Centessa shareholders overwhelmingly approved the scheme of arrangement for the acquisition by Eli Lilly and Company, with 126,653,456 votes for and 23,007 against.
-
Next Milestone: Court Sanction Hearing
The High Court of Justice of England and Wales is scheduled to hold the Court Sanction Hearing on June 22, 2026, which is the final legal step for the acquisition.
-
Routine AGM Proposals Approved
All proposals at the Annual General Meeting, including director re-appointments and auditor ratification, were also approved.
Analysis · CNTA · Life Sciences
Centessa Pharmaceuticals plc shareholders have overwhelmingly approved the scheme of arrangement for its acquisition by Eli Lilly and Company. This vote is a critical step, removing a major contingency and moving the deal closer to its scheduled Court Sanction Hearing on June 22, 2026.
At the time of this filing, CNTA was trading at $39.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $11.77 to $40.26. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.